Get the Stockscreener App
1.11
0.00%
0.00
Immunoprecise Antibodies Ltd stock is traded at $1.11, with a volume of 1.09M.
It is up +0.00% in the last 24 hours and up +107.87% over the past month.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
See More
Previous Close:
$1.11
Open:
$1.14
24h Volume:
1.09M
Relative Volume:
0.65
Market Cap:
$29.93M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-2.3408
EPS:
-0.4742
Net Cash Flow:
$-5.90M
1W Performance:
+10.45%
1M Performance:
+107.87%
6M Performance:
+170.73%
1Y Performance:
+12.12%
1-Day Range:
$1.05
$1.16
1-Week Range:
$0.82
$1.16
52-Week Range:
$0.30
$1.16
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Name
Immunoprecise Antibodies Ltd
Sector
Industry
Phone
-
Address
-
Compare IPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
1.11 | 29.93M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Stock (IPA) Latest News
Market Recap: ImmunoPrecise Antibodies Ltd (IPA)’s Positive Momentum, Closing at 0.95 - DWinneX
We're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn Rate - Yahoo Finance
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Sees Large Growth in Short Interest - Defense World
ImmunoPrecise stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
ImmunoPrecise Antibodies (IPA) Showcases Groundbreaking AI-Desig - GuruFocus
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass - GuruFocus
Esty, America's Car-Mart, ImmunoPrecise - TradingView
ImmunoPrecise’s AI-Designed Peptides Surpass Semaglutide in Receptor Activation - TipRanks
ImmunoPrecise Antibodies Says AI-Designed GLP-1 Peptides Surpass Semaglutide In Receptor Activation - MarketScreener
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies - The Joplin Globe
Immunoprecise Antibodies discovers highly conserved epitope across all four dengue virus serotypes - BioWorld MedTech
ImmunoPrecise jumps on reported vaccine breakthrough - The Pharma Letter
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Up 1.8% – Here’s What Happened - Defense World
ImmunoPrecise identifies universal dengue vaccine target By Investing.com - Investing.com South Africa
ImmunoPrecise Antibodies (IPA) Makes Breakthrough in Dengue Vacc - GuruFocus
Immunoprecise Announces Ai-Driven Breakthrough In Universal Dengue Vaccine Discovery - marketscreener.com
ImmunoPrecise Unveils AI-Driven Breakthrough in Dengue Vaccine Discovery - TipRanks
ImmunoPrecise identifies universal dengue vaccine target - Investing.com
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery | IPA Stock News - GuruFocus
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery - Yahoo Finance
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Upgraded by Wall Street Zen - Defense World
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Eng - GuruFocus
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts - Yahoo Finance
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference | IPA Stock News - GuruFocus
ImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech Conference - TipRanks
AI Breakthrough: ImmunoPrecise CEO Reveals Next-Gen Biotherapeutics Strategy at Major Tech Conference - Stock Titan
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference - New Castle News
What's Going on With Apple Stock? - The Globe and Mail
ImmunoPrecise Antibodies (IPA) Showcases Breakthrough in Epitope Mapping | IPA Stock News - GuruFocus
ImmunoPrecise Antibodies’ LENSai Platform Revolutionizes Epitope Mapping - TipRanks
IPA's LENSai™ Platform Delivers X-Ray--Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed | IPA Stock News - GuruFocus
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - Yahoo Finance
ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Shares Leap 28% Yet They're Still Not Telling The Full Story - simplywall.st
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery - ACCESS Newswire
How ImmunoPrecise Antibodies ($IPA) Uses AI to Transform Antibody-Based Drug Discovery - Podomatic
IPAImmunoprecise Latest Stock News & Market Updates - Stock Titan
Views of Wall Street’s Leading Experts on ImmunoPrecise Antibodies Ltd - Sete News
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Down 7% – Should You Sell? - Defense World
What is going on with ImmunoPrecise Antibodies Ltd? Sentiment Analysis - uspostnews.com
Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely? - simplywall.st
H.C. Wainwright sets $50 target for ImmunoPrecise stock - Investing.com Australia
H.C. Wainwright sets $50 target for ImmunoPrecise stock By Investing.com - Investing.com South Africa
ImmunoPrecise Antibodies’ (IPA) “Buy” Rating Reiterated at HC Wainwright - Defense World
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI- - GuruFocus
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods - 01net
ImmunoPrecise Antibodies Aligns with FDA’s Move to Non-Animal Testing - TipRanks
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSaitm with FDA's Shift to Non-Animal Testing Methods - Lelezard
AI Breakthrough: How IPA's LENSai Platform Leads FDA's Historic Shift from Animal Testing - Stock Titan
ImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody Discovery - TipRanks
Immunoprecise Antibodies Ltd Stock (IPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):